कृपया अन्य खोज का प्रयास करें
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Maged S. Shenouda | 60 | 2020 | Chief Financial Officer |
Paul E. Kelly | 67 | 2015 | Director |
Dan Iosifescu | - | 2020 | Member of Scientific Advisory Board |
John Glasspool | 61 | 2019 | Independent Director |
Charles E. Inturrisi | - | - | Member of Scientific Advisory Board |
Stephen M. Stahl | - | 2020 | Member of Scientific Advisory Board |
Sergio Traversa | 64 | 2012 | CEO & Director |
Maurizio Fava | - | 2017 | Member of Scientific Advisory Board |
Charles J. Casamento | 79 | 2015 | Independent Chairman of the Board |
Thomas P. Laughren | - | 2020 | Member of Scientific Advisory Board |
Luca Pani | - | 2020 | Member of Scientific Advisory Board |
Sanjay Johan Mathew | - | 2020 | Member of Scientific Advisory Board |
Fabiana Fedeli | 53 | 2023 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है